Kedrion Biopharma and BPL participated in the 2023 ISTH Congress, one of the main initiatives of the International Society on Thrombosis and Haemostasis. Kedrion and BPL attended this event for the first time as one united company, and further committed to rare and ultra rare diseases.
The Congress, held in Montréal, Québec (Canada), brought together thousands of the world’s leading experts on thrombosis, hemostasis, and other coagulation disorders who presented the most recent advances in the field, exchanged the latest developments in science and discussed the newest clinical applications designed to improve patient care. In addition, presentations on the diagnosis and treatment of Hereditary Factor X Deficiency and Congenital Plasminogen Deficiency were discussed.
Brian Branchford, MD, Associate Medical Director of the Versiti Medical Sciences Institute (USA), shared the latest results and clinical insights from the “Hereditary Factor X Deficiency in America Survey”. The “HFXD in America Survey” is the first study of its kind to directly assess the challenging HFXD patient journey. Through its focus on diagnosis, treatment, and overall care and well-being, the survey provides insights into patient disease burden and quality of life and the impact on caregivers.
“The impact of rare coagulation disorders on patients and their caregivers is often underrepresented – said Brian Branchford. In addition to clinical data, it is critically important that we better understand how these disorders impact patients’ health and well-being. The “HFXD in America Survey” is an important step along that path for clinicians who provide care for patients with HFXD.”
Karen Thibaudeau, PhD, Kedrion’s Global Medical Therapeutic Area Lead, presented data from her long-term experience on Congenital Plasminogen Deficiency.
Our therapies for Hereditary Factor X Deficiency and for Congenital Plasminogen Deficiency are examples of Kedrion’s growing focus on rare and ultra-rare diseases.
Kedrion places a high value on the welfare of those who benefit from its products, as well as the communities and individuals with whom it collaborates, and works on a global scale to broaden access to plasma therapies.
